Sequana Medical 2021 Investor Presentation - Diuretic-Resistant Fluid Overload

Sequana Medical NV presented its investor deck in January 2021 detailing innovations in treating diuretic-resistant fluid overload across liver disease, malignant ascites, and heart failure. The presentation covers the company's alfapump® system and DSR® therapy platforms, including regulatory status and ongoing clinical investigations.